State of Alaska Department of Revenue Purchases 31,670 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Alaska Department of Revenue lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 213.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,508 shares of the biopharmaceutical company’s stock after buying an additional 31,670 shares during the period. State of Alaska Department of Revenue’s holdings in Halozyme Therapeutics were worth $2,222,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. RPg Family Wealth Advisory LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $1,886,000. Segall Bryant & Hamill LLC increased its holdings in Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares in the last quarter. Retirement Systems of Alabama increased its holdings in Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. South Street Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter worth about $9,812,000. Finally, Foster & Motley Inc. increased its holdings in Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after purchasing an additional 12,630 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.4 %

Shares of NASDAQ:HALO opened at $57.34 on Tuesday. Halozyme Therapeutics, Inc. has a 52-week low of $34.36 and a 52-week high of $65.53. The company has a market capitalization of $7.30 billion, a P/E ratio of 18.99, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a 50-day simple moving average of $51.73 and a 200 day simple moving average of $54.42. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HALO. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.